13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
95 檔
33.9%
As reported in its official Q4 2025 Form 13F filing, Soleus Capital Management, L.P.'s tracked investment portfolio stood at $2.9B with 95 total positions.
In Q4 2025, Soleus Capital Management, L.P. displayed an active expansion posture, initiating 13 new positions and adding to 15 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 13.04% | — | +152.17% | |
| 2 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 8.56% | -0.03% | -7.63% | |
| 3 | CELC | Celcuity Inc | Stock-Other | 6.65% | +0.20% | +53.39% | |
| 4 | NVCR | NovoCure Limited | Stock-Healthcare | 4.07% | +0.55% | -11.55% | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.95% | -2.26% | -57.75% | |
| 6 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.45% | +0.12% | -18.35% | |
| 7 | DXCM | Dexcom Inc | Stock-Healthcare | 3.18% | -0.36% | EXIT | |
| 8 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.89% | -0.75% | +48.26% | |
| 9 | GMED | Globus Medical Inc - A | Stock-Healthcare | 2.86% | -1.27% | +403.98% | |
| 10 | BBNX | Beta Bionics Inc | Stock-Other | 2.85% | +0.60% | -34.51% | |
| 11 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.74% | — | +11.03% | |
| 12 | TWST | Twist Bioscience CORP | Stock-Other | 2.18% | -1.99% | -0.24% | |
| 13 | ORGO | Organogenesis Holdings Inc | Stock-Other | 1.91% | -0.12% | -17.69% | |
| 14 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.74% | -0.40% | +11.68% | |
| 15 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.67% | -1.20% | +285.76% | |
| 16 | PODD | Insulet CORP | Stock-Healthcare | 1.57% | +0.72% | — | |
| 17 | NPCE | Neuropace Inc | Stock-Other | 1.54% | +0.03% | -8.61% | |
| 18 | AXGN | Axogen Inc | Stock-Other | 1.46% | -0.82% | -30.10% | |
| 19 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.42% | -0.07% | +42.91% | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 1.36% | -0.96% | — | |
| 21 | LIVN | LivaNova PLC | Stock-Other | 1.29% | -0.78% | — | |
| 22 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.16% | — | +190.45% | |
| 23 | GERN | Geron CORP | Stock-Other | 1.13% | -0.61% | +34.70% | |
| 24 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.08% | -0.29% | -60.00% | |
| 25 | IMVT | Immunovant Inc | Stock-Other | 1.04% | +0.10% | — | |
| 26 | PCVX | Vaxcyte Inc | Stock-Other | 1.04% | -0.91% | EXIT | |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.03% | -1.42% | +359.02% | |
| 28 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.02% | +1.77% | -58.88% | |
| 29 | VCEL | Vericel CORP | Stock-Other | 1.01% | -1.08% | +53.43% | |
| 30 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.98% | +0.54% | -54.30% | |
| 31 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.95% | — | +42.03% | |
| 32 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.92% | — | +27.52% | |
| 33 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.89% | -0.48% | +291.33% | |
| 34 | FOCL | Edap Tms SA -adr | Stock-Other | 0.89% | +0.20% | — | |
| 35 | TFX | Teleflex Inc | Stock-Healthcare | 0.86% | — | — | |
| 36 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.85% | +0.63% | -49.67% | |
| 37 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.83% | -1.22% | — | |
| 38 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.82% | +0.02% | +71.94% | |
| 39 | PHVS | Pharvaris N.V. | Stock-Other | 0.72% | +0.07% | +8.50% | |
| 40 | IVVD | Invivyd Inc | Stock-Other | 0.70% | -0.18% | — | |
| 41 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.69% | +0.63% | NEW | |
| 42 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.68% | — | — | |
| 43 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.63% | +0.84% | — | |
| 44 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.58% | -0.08% | — | |
| 45 | MBX | Mbx Biosciences Inc | Stock-Other | 0.48% | +0.76% | +48.69% | |
| 46 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.47% | +2.48% | -9.08% | |
| 47 | JBIO | Jade Biosciences Inc | Stock-Other | 0.45% | +0.74% | — | |
| 48 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.42% | -0.02% | +3500.00% | |
| 49 | SION | Sionna Therapeutics Inc | Stock-Other | 0.41% | -0.21% | -35.07% | |
| 50 | SEPN | Septerna Inc | Stock-Other | 0.39% | +0.05% | +1999.50% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +7.2% | +152.17% | Add |
| 2 | CELC | Celcuity Inc | +3.7% | +53.39% | Add |
| 3 | GMED | Globus Medical Inc - A | +2.4% | +403.98% | Add |
| 4 | PRAX | Praxis Precision Medicines I | +1.7% | -57.75% | Trim |
| 5 | MIRM | Mirum Pharmaceuticals Inc | +1.1% | +285.76% | Add |
| 6 | AM6 | Amicus Therapeutics Inc | +0.9% | +11.03% | Add |
| 7 | GSK | Gsk Plc-spon Adr | +0.7% | +190.45% | Add |
| 8 | ALNY | Alnylam Pharmaceuticals Inc | +0.7% | +359.02% | Add |
| 9 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.6% | +291.33% | Add |
| 10 | BMRN | Biomarin Pharmaceutical Inc | +0.5% | +48.26% | Add |
| 11 | TRVI | Trevi Therapeutics Inc | +0.4% | +3500.00% | Add |
| 12 | SEPN | Septerna Inc | +0.4% | +1999.50% | Add |
| 13 | IKT | Inhibikase Therapeutics Inc | +0.3% | +71.94% | Add |
| 14 | RAPT | Rapt Therapeutics Inc | +0.3% | +42.03% | Add |
| 15 | VCEL | Vericel CORP | +0.2% | +53.43% | Add |
| 16 | SNDX | Syndax Pharmaceuticals Inc | +0.2% | +11.68% | Add |
| 17 | NPCE | Neuropace Inc | — | -8.61% | Trim |
| 18 | KRYS | Krystal Biotech Inc | -0.5% | -7.63% | Trim |
| 19 | BLTE | Belite Bio Inc - Adr | -0.5% | -80.78% | Trim |
| 20 | URGN | UroGen Pharma Ltd. | -0.6% | -77.91% | Trim |
| 21 | STAA | Staar Surgical Co | -0.7% | -95.00% | Trim |
| 22 | VCYT | Veracyte Inc | -0.7% | -97.63% | Trim |
| 23 | ANAB | Anaptysbio Inc | -0.7% | -78.44% | Trim |
| 24 | MDGL | Madrigal Pharmaceuticals Inc | -1.6% | -99.27% | Trim |
| 25 | ARGX | Argenx Se - Adr | -1.6% | -54.30% | Trim |
| 26 | INDV | Indivior Pharmaceuticals, Inc. | -1.7% | -93.18% | Trim |
| 27 | INSP | Inspire Medical Systems Inc | -1.7% | -58.88% | Trim |
| 28 | CDTX | Cidara Therapeutics Inc | -2.1% | -92.14% | Trim |
| 29 | UTHR | United Therapeutics CORP | -2.1% | -60.00% | Trim |
| 30 | NVCR | NovoCure Limited | -2.2% | -11.55% | Trim |
| 31 | 430 | Terns Pharmaceuticals Inc | -2.8% | -97.38% | Trim |
| 32 | TGTX | Tg Therapeutics Inc | -3.5% | -18.35% | Trim |
| 33 | DXCM | Dexcom Inc | — | NEW | New buy |
| 34 | ELV | Elevance Health Inc | — | EXIT | Sold out |
| 35 | PODD | Insulet CORP | — | NEW | New buy |
| 36 | ALKS | Alkermes plc | — | NEW | New buy |
| 37 | LIVN | LivaNova PLC | — | NEW | New buy |
| 38 | IMVT | Immunovant Inc | — | NEW | New buy |
| 39 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 40 | GRFS | Grifols Sa-adr | — | EXIT | Sold out |
| 41 | TFX | Teleflex Inc | — | NEW | New buy |
| 42 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 43 | IART | Integra Lifesciences Holding | — | EXIT | Sold out |
| 44 | IVVD | Invivyd Inc | — | NEW | New buy |
| 45 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
| 46 | THC | Tenet Healthcare CORP | — | NEW | New buy |
| 47 | RCUS | Arcus Biosciences Inc | — | NEW | New buy |
| 48 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 49 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 50 | ADMA | Adma Biologics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 95 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, KRYS, CELC) accounted for 33.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
DXCM
市值: $86.1M
Top Position Liquidated / Trimmed
ELV
前期市值: $83.9M
During Q4 2025, Soleus Capital Management, L.P.'s top holdings by market value included XBI (13.0%)、KRYS (8.6%)、CELC (6.7%). The largest single position, XBI, represented 13.0% of total portfolio value.
In Q4 2025, Soleus Capital Management, L.P. made 50 total portfolio adjustments, initiating 13 new buys, adding to 15 positions, trimming 17 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.